Jennifer S McDonald1, Robert J McDonald2, John C Lieske3, Rickey E Carter4, Richard W Katzberg5, Eric E Williamson2, David F Kallmes6, David E Kallmes6. 1. Department of Radiology, Mayo Clinic, Rochester, MN. Electronic address: mcdonald.jennifer@mayo.edu. 2. Department of Radiology, Mayo Clinic, Rochester, MN. 3. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. 4. Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 5. Department of Radiology, Medical University of South Carolina, Charleston. 6. Department of Radiology, Mayo Clinic, Rochester, MN; Department of Neurosurgery, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: To examine the effect of intravenous iodinated contrast material administration on the subsequent development of acute kidney injury (AKI), emergent dialysis, and short-term mortality using a propensity score-adjusted analysis of computed tomographic scan recipients with chronic kidney disease (CKD). PATIENTS AND METHODS: In this institutional review board-approved retrospective study, all patients with CKD who received a contrast-enhanced (contrast group) or unenhanced (noncontrast group) computed tomographic scan from January 1, 2000, to August 1, 2013 were identified. Patients were subdivided into CKD stage III (baseline estimated glomerular filtration rate, 30-59 mL/min per 1.73 m(2)) and CKD stage IV-V (baseline estimated glomerular filtration rate, <30 mL/min per 1.73 m(2)) subgroups and separately underwent propensity score generation, stratification, and 1:1 matching. Rates of AKI, 30-day emergent dialysis, and mortality were compared between contrast and noncontrast groups. Sensitivity analyses examining only patients with stable prescan serum creatinine levels and incorporating intravenous fluid administration at the time of the CT scan into the model were also performed. RESULTS: A total of 6902 patients (4496 CKD stage III, matched: 1220 contrast and 1220 noncontrast; 2086 CKD stage IV-V, matched: 491 contrast and 491 noncontrast) were included in the study. After propensity score adjustment, rates of AKI, emergent dialysis, and mortality were not significantly higher in the contrast group than in the noncontrast group in either CKD subgroup (CKD stage III: OR, 0.65-1.00; P<.001-.99 and CKD stage IV-V: OR, 0.93-2.33; P=.22-.99). Both sensitivity analyses revealed similar results. CONCLUSION: Intravenous contrast material administration was not associated with an increased risk of AKI, emergent dialysis, and short-term mortality in a cohort of patients with diminished renal function.
OBJECTIVE: To examine the effect of intravenous iodinated contrast material administration on the subsequent development of acute kidney injury (AKI), emergent dialysis, and short-term mortality using a propensity score-adjusted analysis of computed tomographic scan recipients with chronic kidney disease (CKD). PATIENTS AND METHODS: In this institutional review board-approved retrospective study, all patients with CKD who received a contrast-enhanced (contrast group) or unenhanced (noncontrast group) computed tomographic scan from January 1, 2000, to August 1, 2013 were identified. Patients were subdivided into CKD stage III (baseline estimated glomerular filtration rate, 30-59 mL/min per 1.73 m(2)) and CKD stage IV-V (baseline estimated glomerular filtration rate, <30 mL/min per 1.73 m(2)) subgroups and separately underwent propensity score generation, stratification, and 1:1 matching. Rates of AKI, 30-day emergent dialysis, and mortality were compared between contrast and noncontrast groups. Sensitivity analyses examining only patients with stable prescan serum creatinine levels and incorporating intravenous fluid administration at the time of the CT scan into the model were also performed. RESULTS: A total of 6902 patients (4496 CKD stage III, matched: 1220 contrast and 1220 noncontrast; 2086 CKD stage IV-V, matched: 491 contrast and 491 noncontrast) were included in the study. After propensity score adjustment, rates of AKI, emergent dialysis, and mortality were not significantly higher in the contrast group than in the noncontrast group in either CKD subgroup (CKD stage III: OR, 0.65-1.00; P<.001-.99 and CKD stage IV-V: OR, 0.93-2.33; P=.22-.99). Both sensitivity analyses revealed similar results. CONCLUSION: Intravenous contrast material administration was not associated with an increased risk of AKI, emergent dialysis, and short-term mortality in a cohort of patients with diminished renal function.
Authors: Elizabeth F O Kern; Miriam Maney; Donald R Miller; Chin-Lin Tseng; Anjali Tiwari; Mangala Rajan; David Aron; Leonard Pogach Journal: Health Serv Res Date: 2006-04 Impact factor: 3.402
Authors: Sophia Zoungas; Toshiharu Ninomiya; Rachel Huxley; Alan Cass; Meg Jardine; Martin Gallagher; Anushka Patel; Ali Vasheghani-Farahani; Gelareh Sadigh; Vlado Perkovic Journal: Ann Intern Med Date: 2009-11-03 Impact factor: 25.391
Authors: Robert J McDonald; Jennifer S McDonald; Rickey E Carter; Robert P Hartman; Richard W Katzberg; David F Kallmes; Eric E Williamson Journal: Radiology Date: 2014-09-09 Impact factor: 11.105
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Edwin A Takahashi; David F Kallmes; Kristin C Mara; William S Harmsen; Sanjay Misra Journal: Diagn Interv Radiol Date: 2018-11 Impact factor: 2.630
Authors: Jennifer S McDonald; Robert J McDonald; Eric E Williamson; David F Kallmes; Kianoush Kashani Journal: Intensive Care Med Date: 2017-02-17 Impact factor: 17.440
Authors: Ulf Nyman; Joanna Ahlkvist; Peter Aspelin; Torkel Brismar; Anders Frid; Mikael Hellström; Per Liss; Gunnar Sterner; Peter Leander Journal: Eur Radiol Date: 2018-08-21 Impact factor: 5.315
Authors: Edwin A Takahashi; David F Kallmes; Chad J Fleming; Robert J McDonald; Michael A McKusick; Haraldur Bjarnason; William S Harmsen; Sanjay Misra Journal: J Vasc Interv Radiol Date: 2017-09-22 Impact factor: 3.464
Authors: J Latus; V Schwenger; G Schlieper; H Reinecke; J Hoyer; P B Persson; B A Remppis; F Mahfoud Journal: Internist (Berl) Date: 2020-12-21 Impact factor: 0.743